FDAnews Drug Daily Bulletin

Barr Challenges Patent Covering Solodyn Drug

Jan. 14, 2009
A A
Medicis Pharmaceutical has received notice that Barr Laboratories has filed an ANDA to market a generic version of Medicis’ once-daily, oral acne treatment Solodyn — a drug that is the subject of a citizen petition. Barr’s application includes a Paragraph IV certification on the ’838 patent that covers Solodyn (minocycline HCl) extended-release tablets in 45-, 90- and 135-mg strengths and expires in 2018, according to a Medicis SEC filing.
Generic Line